Skip to content.Skip to side navigation. Quick Navigation: Skip to content.Skip to side navigation.
GPO Access Home Page.
Jump to selected topic.
Navigation Bar
About.Help. A-Z Resource List. Locate a Federal Depository Library. Buy Publications. Legislative. Executive. Judicial.
National Archives and Records Administration logo.
Database Features.
Browse
Simple Search
Advanced Search
* Boolean
  * Proximity
Search History
Search Tips
Corrections

Latest Updates

User Info
FAQs
Agency List
Incorporation by Reference
e-CFR Main Page
Related Resources
Code of Federal Regulations
Federal Register
List of CFR
Sections Affected
Regulations.gov
Unified Agenda
All NARA Publications
About Government.
Ben's Guide Logo.
Get Adobe Reader

blue pill
e-CFR Data is current as of November 19, 2009


Title 21: Food and Drugs
PART 740—COSMETIC PRODUCT WARNING STATEMENTS
Subpart B—Warning Statements

Browse Previous | Browse Next

§ 740.12   Feminine deodorant sprays.

(a) For the purpose of this section, the term “feminine deodorant spray” means any spray deodorant product whose labeling represents or suggests that the product is for use in the female genital area or for use all over the body.

(b) The label of a feminine deodorant spray shall bear the following statement:

Caution —For external use only. Spray at least 8 inches from skin. Do not apply to broken, irritated, or itching skin. Persistent, unusual odor or discharge may indicate conditions for which a physician should be consulted. Discontinue use immediately if rash, irritation, or discomfort develops.

The sentence “Spray at least 8 inches from skin” need not be included in the cautionary statement for products whose expelled contents do not contain a liquified gas propellant such as a halocarbon or hydrocarbon propellant.

(c) Use of the word “hygiene” or “hygienic” or a similar word or words renders any such product misbranded under section 602(a) of the Federal Food, Drug, and Cosmetic Act. The use of any word or words which represent or suggest that such products have a medical usefulness renders such products misbranded under section 502(a) of the Act and illegal new drugs marketed in violation of section 505 of the Act.

[40 FR 8929, Mar. 3, 1975]

Browse Previous | Browse Next